Gland Pharma Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dj0glu7heamsg13d8wn801nd.pdf

Key Takeaways


Growth Drivers & Guidance

Srinivas Sadu: "FY '29 will be one big step up. A couple of complex products, which are big ones, will be launched probably third, second or third quarter FY '29. That could be one big step up."

Cenexi Turnaround

Srinivas Sadu: "The revenue increase may not be that great, probably, but mostly on the profitability, the improvement should be -- what you are seeing is more on the efficiency side."

GLP-1: The Ex-Guidance Upside

Srinivas Sadu: "We are not actually talking any numbers for GLP. Even the guidance we're giving is excluding GLP because it all depends on these partners getting approvals in different markets and volumes."

Margins & Cost Efficiency

Ravi Mitra: "This will be sustainable in terms of long term."

U.S. & Base Business


Strategic Investments & Capex

Srinivas Sadu: "So there are multiple reasons why we acquired this, not just the business what they have. So as we speak, we have already started developing some hormone products. Now we're looking at the controlled substances, which you can't do in India, signing contracts with customers of Cenexi for our products and our own products getting launched in."

Guidance & Commitments

CommitmentSpecificsTimeline
Consolidated revenue growth12%–13% constant-currency growth, excluding GLP-1FY27
Consolidated EBITDA marginAround 25%–26%FY27
Base business EBITDA margin33%–35%FY27
Cenexi EBITDA marginMid-to-high single digitsFY27-end
Cenexi revenueApproximately EUR20 crFY27
Cenexi medium-term EBITDA marginMid-teenMedium term
Major CDMO project commercializationAnnual revenue potential USD2.5 cr–USD3 crH2 FY28
FY28 consolidated growth15%FY28
FY29 growth step-up19%–20% or more, driven by complex product launchesQ2/Q3 FY29
GLP-1 ramp-upFull ramp-up post-U.S. patent expiry; insulin contract fills capacity in interimPost-2030
CapexINR2,000 cr over five years; INR500 cr in FY27FY27–FY31
Saudi Arabia shipmentsMay resume if geopolitical situation cools downNext quarter

Key Metrics

MetricQ4 FY26
Consolidated revenue₹1,742.8 cr, +22% YoY
Full year FY26 consolidated revenue₹6,430.7 cr, +14.5% YoY
Adjusted EBITDA₹524.4 cr, margin 30%, +500 bps YoY
Full year FY26 adjusted EBITDA₹1,682.6 cr, margin 26%, +360 bps YoY
Adjusted PAT₹366.7 cr, margin 21% vs 13% in prior year
Full year FY26 adjusted PAT₹1,045.5 cr, margin 16% vs 12% in prior year
Consolidated gross margin66%, +30 bps YoY
Base business gross margin62%, +90 bps YoY
Base business adjusted EBITDA margin41% for Q4, 38% for full year FY26
US revenue₹971.6 cr, +26% YoY; full year ₹3,318.1 cr, +11%
Europe and other regulated markets revenue₹79.4 cr; full year ₹324.9 cr, +11%
Rest of world revenue₹146.8 cr, +17% YoY; full year ₹651.1 cr, +7%
India revenue₹67 cr; full year ₹267.2 cr
Cenexi revenueEUR4.5 cr, +4% YoY; full year EUR18.2 cr, +11%
Cenexi EBITDAEUR0.1 cr, EBITDA positive
CDMO share of total revenue46%, +28% growth; base business CDMO at 23% of base revenue, +33%
R&D spend₹50.6 cr, ~4% of base business sales; full year ₹223 cr, 5% of base business revenue
US product launches in FY2631 products launched, including 5 in Q4
US ANDA filings and approvals in FY2624 ANDAs filed, 28 approvals received
Cash and cash equivalents₹3,359.1 cr as of March 31, 2026
Cash flow from operations₹404.5 cr for Q4; full year ₹1,031.4 cr vs ₹914.7 cr in FY25
Cash conversion cycle164 days for FY26, improved YoY
Total capex FY26₹493.8 cr
Effective tax rate28% for Q4; full year ~29%
GLP-1 cartridge capacity14 cr units; 8 contracts signed, 6–7 more expected
Cenexi external debt₹243.4 cr
Consolidated growth guidance FY2712%–13% on constant currency, excluding GLP-1
Consolidated CAGR target next four years15%
Cenexi midterm EBITDA targetMid-teen EBITDA level
Base business EBITDA margin guidance33%–35%; consol EBITDA margin guided at 25%–26%
Capex outlay over next five years₹2,000 cr
FY27 expected capex~₹500 cr
Major CDMO project annual revenue potentialUSD2.5 cr to USD3 cr, commercialization expected H2 FY28
Cenexi FY27 revenue target~EUR20 cr
Other income₹111.5 cr for Q4; full year ₹316.3 cr
Profit share and milestone revenue mix9% profit share, 6% milestone
Cenexi Fontenay capacity utilization~100%; Osny solid orals ~90%; other two sites 50%–60%
Insulin capacity utilization on cartridge line3 cr to 4 cr units expected over next couple of years